



majority of readers will be looking at individual chapters or
using this as a reference text, thus repetition is inevitable to
ensure comprehensiveness in the individual chapters. The
chapter by Petros and Peters on dose intensity to overcome
drug resistance deals with resistance more by implication
than by direct reference to resistance data, and avoids dealing
with the controversies. The chapters on molcular mechan-
isms of anti-oestrogen resistance and tamoxifen metabolism
from the groups Jordon and Osborne unfortunately lack the
more recent data on non-isomerisable tamoxifen derivatives,
which is an important component of the current interpreta-
tion of data from this field. This illustrates a more general
point: throughout there are almost no references beyond
1992. The two chapters on progestins and anti-progestins
have few data on resistance to these compounds, but they
provide a useful summary of data from in vitro models.
Part 3, dealing with chemotherapeutic drugs, has
substantial overlap throughout some of the chapters on
multi-drug resistance and the importance of MDRI. The
chapter by Goldstein is in itself quite exhaustive, taking this
area from the molecular through to importance in clinical
trials. It goes outside of the breast cancer area dealing
substantially with areas where MDRl involvement is
apparently more important. Further chapters on non-
MDRl-associated resistance include the importance of extra
chromosomal DNA, which is somewhat speculative in
contrast to the chapter on fluoropyrimidine chemotherapy
which deals with quite well-known data. The chapter by
Harris and Carmichael gives a comprehensive discussion
specifically on topoisomerase inhibitors, as well as reflecting
on the relevance ofmultidrug resistance mechanisms to them.
Weisenthal provides a valuable discussion for those
interested in in vitro tests to predict breast cancer sensitivity
to these agents. This particular chapter is unusual in this
book in that the tables are poorly annotated and reduced in
value as a result of that.
The last two chapters on approaches to reversing multi-
drug resistance could have been excluded since they are
highly repetitive of other chapters in this section.
The three chapters on chemohormonal interactions deal
with separate issues: (i) the relationship between cell kinetics
and hormonal receptors and their utility for treatment
selection; (ii) hormonal synchronisation before chemother-
apy, reflecting that this has proven to be uniformly without
benefit; (iii) an extensive laboratory-orientated discussion of
the interactions of chemo- and hormonal therapy in cell
culture. It would have been valuable either within the context
of this last chapter or possibly by the inclusion of an extra
chapter to have given a further discussion of the interaction
of these drugs in vivo, particularly since the 'overview'
analysis of 1992 of adjuvant treatments in breast cancer
provided compelling indirect evidence on the additive effects
of these two approaches in the adjuvant setting.
Overall Ifoundittobehighlyreadableandvaluable, and the
wide interest ofsuch a text was emphasised to me by the large
number ofpeople that picked up the book while I wascarrying
it with me over a period of some weeks. Many of them
requested details in order that theycould purchase it. I for one,
will be guarding this book in my cabinet carefully since I am
sure that it is one ofthose which will walk very easily.
M Dowsett
Noo-Reproductive Actioi of Sex Steroids
Edited by GR Bock and JA Goode, John Wiley & Sons:
Chichester, 1995, 307pp. £49.95, ISBN 0 471 95513 2.
CIBA FOUNDATION SYMPOSIUM 191:
NON-REPRODUCTIVE ACTIONS OF SEX STEROIDS
The reports of the Ciba Foundation Symposia always make
interesting reading, dealing as they do with topics at the
leading edge of science or medicine, and bringing together
leading investigators in the area. This meeting, held in August
1994, is no exception. It turns the spotlight away from the
reproductive aspects ofthe sex steroids, which havejustifiably
attracted extensive exploration, and focuses it on the wider
role that these hormones play in a variety of other
physiological processes.
In the first paper, Miguel Beato reviews our knowledge of
how steroid hormones modulate the expression of a variety
of genes by binding to hormone-responsive elements of DNA
or interacting with various transcription factors to influence
signal transduction pathways. The interactions of hormone,
receptor and the several other factors involved are complex,
and an important mechanism may involve the hormone itself
changing the chromatin structure. Similarly, the concept of
antihormones occupying the receptor site, thereby preventing
hormone action, may be only one of several possible
mechanisms, and specific binding sites for antihormones
may also exist.
Etienne-Emile Baulieu points out that non-genomic
mechanisms of hormone action are also important. Effects
of membrane interaction and changes in membrane structure
have been noted, and the role of binding proteins influencing
intracellular machinry is still unclear. There are several
examples of progestagens influencing biochemical activity at
the membrane and also modulating calcium entry into cells.
Bruce McEwen discusses neural effects of steroids. Apart
from their well-known role in reproduction, they also affect
pain perception, cognitive function and mood. Oestradiol
induces choline acetyltransferase activity in the forebrain
and reduces synapse density. The mechanism is unclear, only
a few classical oestrogen receptors exist in pyramidal cells,
although the oestrogen receptor may perhaps be atypical.
Interestingly, hormone replacement therapy (HRT) has been
reported to ameliorate the symptoms of Alzheimer's disease.
Michael Schumacher discusses the role of sex steroids in
nerve repair. Progesterone is actively synthesised and
metabolised in brain tissue, and the hormone or its
metabolites may accelerate the repair of myelin sheaths
after injury.
Thereisalesserincidenceofcoronaryheartdiseaseinwomen
than in men. It is likely that oestradiol is a major factor, the
mechanism, in part, involving lipoprotein changes. Francis
Bayard's paperpoints out thatdirect effects on the blood vessel
wall should not be ruled out. The enzymes that synthesise and
metaboliseoestrogensarepresent onthevascularwall, andtheir
effects on cytokines, growth factors and vasoregulatory
molecules are probably involved in the pathogenesis of
arteriosclerosis. Following this theme, Marie Foegh presents
data on transplant arteriosclerosis, which is a major clinical
problem. Oestradiol profoundly influences the immune system
anditisnotablethatwomenaremoresusceptibletoautoimmune
diseases than men are. Oestrogens enhance the differentiation
and maturation oflymphocytes and diminish suppressor T-cell
function. Intransplantpatients, HRTisanunfavourablefactor.
However, in an animal modeL oestradiol inhibited myointimal
hyperplasia and prevented entry of macrophages, which is
probably the initiating factor. Thus, oestradiol has complex
effectsonthevascularsystem,stillnotwelldefinedorunderstood.
Madge Vickers reports that coronary heart disease is the
most common cause ofdeath in post-menopausal women and
that some protection is given by HRT. She describes a
proposed epidemiological study of users of HRT in the UK
and elsewhere in Europe, which would address many of the
unanswered questions, including the effect of HRT on
vascular disease. The problems with such a trial are
considerable (e.g. changing fashions in dose, type of steroid,
route of administration) but if the trial were postponed, no
answer would ever be forthcoming.
Torbjorn Backstrom considers the effects of oestrogen on
mooyd. Progestogens may increase depression, and progester-
one and some of its metabolites can cause anaesthesia.
Indeed, this observation has been used in clinical practice.
Oestrogens can alter sensory perception, locomotory activity*
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and balance, and may also cause memory improvement in
some patients.
Osteoporosis is a major problem in post-menopausal
women. Stavros Manolagas explains that bone marrow cells
possess classical oestrogen receptors; both androgens and
oestrogens suppress interleukin 6 (IL-6) and, after oestrogen
is reduced, the increase in IL-6 causes an increase in
osteoclast production. Conversely, IL-6 suppression de-
creases bone loss.
Women suffer disproportionately from autoimmune
diseases, and Howard Fox explains that androgens and
oestrogens are probably the major determinants of this
phenomenon. In rats, androgen was necessary to maintain
low levels of autoantibodies, and treatment with androgens
prevents diabetes. The sex hormones act by altering gene
expression; oestrogen treatment positively regulated the
gamma-interferon promoter.
Many breast tumours are hormone responsive in the sense
that they are dependent on oestrogen for their growth and
development. Oestrogen deprivation is still the keystone of
treatment. However, sooner or later tumour cells lose their
hormone dependence and escape therapeutic control. Kate
Horwitz suggests that this is because the cells have altered
responsiveness through changes in the regulatory mechan-
isms; this may be due to activation ofinhibitors by oestrogen
metabolites. Progesterone receptors exist in two functionally
different (inhibitory and activatory) forms that interact. In
discussion, it was accepted that translation of experimental
data to in vivo models is difficult but all these experiments
offered an insight into specific aspects of oestrogen action in
breast cancer.
Several oestrogen-induced proteins occur in oestrogen
receptor-positive cancers. Henri Rochefort explains that
some had prognostic significance, particularly pS2 and
cathepsin D, a lysosomal protease. Oestrogen also modulates
transcription of various genes, and the oestrogen receptor
and various transcription factors interact.
Prostate cancer is common in older men, and testosterone
is closely involved in the development and growth of these
tumours. Using prostate cancer cell lines in vitro, Luigi
Castagnetta had examined the role of oestradiol and showed
that some cell lines are inhibited in their growth by
oestradiol, whereas others are stimulated. This hormone
may act synergistically with testosterone. The mechanism by
which androgens act does not seem to involve an androgen
receptor. Oestrogen receptors were clearly shown to be
present in prostate cancer cells and so the mechanism
presumably involves activation of oestrogen receptor and
transforming growth factor beta, as growth can be blocked
by antibodies to this growth factor.
What emerges from this meeting is that oestrogens and
androgens have multiple effects on a variety of tissues, not
just those classically recognised and defined as 'target
tissues'. The brain, cardiovascular system, muscle, bone,
the immune system and many other tissues are apparently
influenced, albeit subtly in some cases, by sex steroids.
Equally striking is the emerging concept that hormones may
exert their effects not only by direct interaction with receptor
proteins, which then activate the appropriate biosynthetic
events, but also by modulating a large variety of intra- and
extracellular control mechanisms which, in turn, can control
the signalling mechanisms. We are only just starting to
discover the extent and complexity of this aspect of
hormone action.
VHT James
Novel Appraches in Anticancer Drug Desgn
WJ Zeller, MD D'Incalci and DR Newell (eds.) Karger,
Basle: 1995, 195 pp. $143.50
Symposia, however well organised, are usually a mix of up-
to-date presentations describing novel and interesting results
and, at the other end of the scale, fairly boring accounts of
work already completed and out of date. This volume is an
account of the proceedings of that part of a joint symposium
between the German Cancer Centre and the EORTC devoted
to new approaches in drug design and, as expected, is a
curate's egg mix of interesting new data and material from
the ark. The first seven chapters make an interesting read and
deal with the design of new drugs using computational
chemistry and molecular modelling based on a knowledge of,
for example, the crystal structure ofreceptors. The chapter by
CW v d Leith and his colleagues sums up the state of the art
of this approach. Twelve years ago the expectations of
computer-supported drug design were enormously high but
'the fall was deep when it was recognised that computational
methods alone cannot predict reliable new lead structures'.
T1his is true, of course, but with the introduction of
combinatorial chemistry, for example, and user-friendly
computer programs to study receptor-drug interactions at
the atomic level one can predict that this will be an important
future approach. Indeed, drugs are already in the clinic that
have been uncovered by these methods and, should they
prove to be superior to analogues discovered by screening or
biochemical approaches, then one would expect programs
dedicated to discovering agents acting on abnormal pathways
in cancer such as the work described on the active site of
protein kinase C or o6 methyltransferase to expand rapidly.
Apart from some interesting findings with suramin, the
middle of the book is disappointing in that it deals with
rather mundane approaches involving cisplatin and other
conventional anti-cancer agents and attempts to improve
their selectivity by the design of analogues, the use of
combinations or attempts to overcome resistance. The Cancer
Chemotherapy Annual deals with these approaches each year
and this volume adds nothing that is either new or exciting.
The book perks up towards the end with some interesting
presentations on the bisphosphonates, bioreductives, steroid
carriers of BCNU and new agents for BNCT (boron neutron
capture therapy), an old approach but one which is now
being reapplied clinically on the basis ofsound scientific data.
T Connors
Cancer of the Bat (4th edn)
Edited by WL Donegan and JS Spratt
WB Saunders Company: 1995, 860 pp. £115,
ISBN 0-7216-4694-8
This is a comprehensive text that is clear and well written by
the contributors. Many of the chapters are written by the
editors and draw on their experience as well as being well
referenced.
The book is well organised and begins with an entertaining
historical account of breast cancer, tracing the origins of
treatment to the earliest records available.
The subsequent chapters then describe the basic sciences of
anatomy, physiology and pathology of the breast and serve
as a useful source of reference. The often confusing area of
benign breast disorders and the overlap with pathology is
then tackled and clarified in chapters 6 and 7, with a helpful
description of abnormalities of normal breast development
and involution (ANDI).
The text then describes the epidemiology and aetiology of
breast cancer in a clear and concise way. Chapter 10
describes the diagnosis of breast cancer and draws on the
author's (Donegan) own experience. The section is well
illustrated with line drawings demonstrating clear examina-
tion and surgical techniques. The following chapter (11)
similarly gives an account of imaging, again combining
experience with referenced data. The author (Moskowitz)
writes authoritatively, describing the development of imaging
techniques and screening. This section also describes
ultrasound needle localisation techniques as well as other